FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
Among patients with glaucoma, diffuse rather than focal glaucomatous macular damage was associated with diminished facial recognition and contrast sensitivity, according to results of a cohort study ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results